ENABLING NEW, FASTER, & LESS EXPENSIVE DRUG DISCOVERY THROUGH THE NEXT GENERATION OF MICROBIOME ACCESS

Problem - Current Drug Discovery Approaches Are Failing
Driving Up Costs – with Limited New Products

New Microbiome Approach Has Dramatic Benefits

Larger Opportunity
Unprecedented access to the hidden drug-like molecules for therapeutic, agricultural and cosmetic opportunities

Time & Cost Reduction
Most efficient and effective discovery method ever devised.

Biologically Relevant
Small molecules from microbiome are already preoptimized by nature and have higher probabilities of success in the clinic

Capital Requirements to Create Platform
Strong Management Team, Board and Advisors

Initial Funding Research 2009-16

Proof 2016-18

Current Raise

$20M Seed Funding
- $11 M Equity Capital (Private Investors)
- $9 M Grants

$15M Series A
- $1.5M to create extensive microbiome library
- $2.5M to advance current molecules toward clinical testing (IND)
- $11M to establish large scale microbiome processing system
- Cash flow breakeven within 36 months

Big Market, Multiple $100B Segments

Pharma
Immuno-modulating
Neuro/CNS
Oncology
Infectious
Metabolic
Rare & Orphan
Non-Pharma
Agrochemical
Cosmetics / Consumer
Industrial Chemical
Oil / Gas

Early Revenue from
- Upfront Payments
- Partnerships
- Milestone Payments
- Royalties

Prolific Producer of IP

Initial Customer & Partner Interest
Established relationships with leading academic & clinical research organizations

Academic Institutions
- UC San Diego
- Harvard Medical School
- MD Anderson
- The James
- The Ohio State University
- Calbi
go
- Charles River
- Amri
- Merck/Serono
- Novartis
- Janssen
- Elanco
- Johnson & Johnson
- Waters
- Agilent
- Waters
- Waters
- Waters
- Waters
- Waters

Partners
- Agilent
- Waters
- Waters
- Waters
- Waters
- Waters
- Waters
- Waters
- Waters
- Waters

Prospective Customers
- DHS
- Contracting with DHS for $1M Services Agreement
- as well as licensing discussions with leading Agricultural leaders

Financial Results, Projections ($000) FYE March

<table>
<thead>
<tr>
<th></th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>REVENUE</td>
<td>0</td>
<td>0</td>
<td>800</td>
<td>10,500</td>
<td>25,000</td>
</tr>
<tr>
<td>PROFIT BEFORE TAX</td>
<td>-1,300</td>
<td>-1,200</td>
<td>-1,800</td>
<td>1,000</td>
<td>6,000</td>
</tr>
</tbody>
</table>